Abstract
Serotonin (5-HT) receptors are part of the G protein-coupled and ligand-gated ion channel families. 5-HT exerts its diverse actions by binding to cell surface receptors which can be classified into seven distinct families (5-HT1 to 5- HT7) according to their structural diversity and mode of action. Some of the 5-HT families are comprised of multiple receptors which share similar structural and mechanistic properties but display very different operational profiles. Evidence continues to mount in support of the important roles of the 5-HT receptors in various neuropsychiatric disorders such as anxiety, depression, schizophrenia, migraine and drug addiction. The 5-HT receptors may also play an important role in obesity, aggression, sexual behaviour and cardiovascular disorders. A number of selective/non-selective 5-HT agonist and antagonist ligands (drugs) have been developed to challenge many of these disease states.
Keywords: 5-Hydroxytryptamine, serotonin, central nervous system (CNS), anti-migraine drugs, G-proteins, 5-HT receptor family
Current Pharmaceutical Design
Title: 5-Hydroxytryptamine (5-HT) Receptor Ligands
Volume: 13 Issue: 25
Author(s): Sean L Kitson
Affiliation:
Keywords: 5-Hydroxytryptamine, serotonin, central nervous system (CNS), anti-migraine drugs, G-proteins, 5-HT receptor family
Abstract: Serotonin (5-HT) receptors are part of the G protein-coupled and ligand-gated ion channel families. 5-HT exerts its diverse actions by binding to cell surface receptors which can be classified into seven distinct families (5-HT1 to 5- HT7) according to their structural diversity and mode of action. Some of the 5-HT families are comprised of multiple receptors which share similar structural and mechanistic properties but display very different operational profiles. Evidence continues to mount in support of the important roles of the 5-HT receptors in various neuropsychiatric disorders such as anxiety, depression, schizophrenia, migraine and drug addiction. The 5-HT receptors may also play an important role in obesity, aggression, sexual behaviour and cardiovascular disorders. A number of selective/non-selective 5-HT agonist and antagonist ligands (drugs) have been developed to challenge many of these disease states.
Export Options
About this article
Cite this article as:
Kitson L Sean, 5-Hydroxytryptamine (5-HT) Receptor Ligands, Current Pharmaceutical Design 2007; 13(25) . https://dx.doi.org/10.2174/138161207781663000
DOI https://dx.doi.org/10.2174/138161207781663000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Comparative Proteomics and Bioinformatics Analysis of Tissue from Non-Small Cell Lung Cancer Patients
Current Proteomics Nanoemulsion for Migraine Prophylaxis Nasal Drug Delivery: Preparation, Characterization and in vitro Evaluation
Pharmaceutical Nanotechnology Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond
Current Pharmaceutical Biotechnology Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment
Current Alzheimer Research Hypoxia and Fetal Heart Development
Current Molecular Medicine Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design High Risk of One-year Stroke Recurrence in Patients with Younger Age and Prior History of Ischemic Stroke
Current Neurovascular Research Vascular Injury During Elevated Glucose can be Mitigated by Erythropoietin and Wnt Signaling
Current Neurovascular Research Preface
Current Medicinal Chemistry Using Small Peptide Segments of Amyloid-β and Humanin to Examine their Physical Interactions
Protein & Peptide Letters Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry An Update on Human Stem Cell-Based Therapy in Parkinson's Disease
Current Stem Cell Research & Therapy DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy
Current Pharmacogenomics Recent Knowledge on Molecular Components of Lewy Bodies Discloses Future Therapeutic Strategies in Parkinsons Disease
Current Drug Targets - CNS & Neurological Disorders Aquaporins in Sensory and Pain Transmission
Current Neuropharmacology (Section B: Integrated Function of Drug Transporters In Vivo) Drug Transport at the Blood-Brain Barrier and the Choroid Plexus
Current Drug Metabolism Cytotoxicity and Anti-Inflammatory Effects of Polyherbal Formulations, Joint Pain Spl and Rumalaya Forte on Lipopolysaccharide Induced Inflammation in IC-21 Macrophages
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
CNS & Neurological Disorders - Drug Targets